RMR Wealth Builders Decreases Position in Boston Scientific Corporation $BSX

RMR Wealth Builders trimmed its position in shares of Boston Scientific Corporation (NYSE:BSX) by 1.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,517 shares of the medical equipment provider’s stock after selling 114 shares during the quarter. RMR Wealth Builders’ holdings in Boston Scientific were worth $915,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. NS Partners Ltd boosted its position in Boston Scientific by 1.6% during the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock worth $37,143,000 after purchasing an additional 5,704 shares in the last quarter. Reliant Investment Partners LLC purchased a new stake in Boston Scientific during the first quarter worth $237,000. Ascent Group LLC boosted its position in Boston Scientific by 226.5% during the first quarter. Ascent Group LLC now owns 49,942 shares of the medical equipment provider’s stock worth $5,038,000 after purchasing an additional 34,645 shares in the last quarter. Bank Pictet & Cie Europe AG boosted its position in Boston Scientific by 40.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider’s stock worth $6,529,000 after purchasing an additional 21,173 shares in the last quarter. Finally, Axiom Investors LLC DE boosted its position in Boston Scientific by 26.8% during the first quarter. Axiom Investors LLC DE now owns 4,759,258 shares of the medical equipment provider’s stock worth $480,114,000 after purchasing an additional 1,006,828 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on BSX shares. Truist Financial boosted their target price on Boston Scientific from $120.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, July 24th. Leerink Partnrs upgraded Boston Scientific to a “strong-buy” rating in a research report on Monday, June 16th. UBS Group upped their price objective on Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Thursday, July 24th. Royal Bank Of Canada restated an “outperform” rating on shares of Boston Scientific in a research report on Thursday, July 24th. Finally, Wells Fargo & Company upped their price objective on Boston Scientific from $118.00 to $124.00 and gave the company an “overweight” rating in a research report on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $118.04.

Boston Scientific Stock Performance

NYSE BSX opened at $102.71 on Monday. The business’s 50-day moving average price is $104.86 and its 200 day moving average price is $102.27. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50. The company has a market capitalization of $152.19 billion, a PE ratio of 61.14, a price-to-earnings-growth ratio of 2.47 and a beta of 0.65. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the prior year, the business posted $0.62 earnings per share. The firm’s revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at $18,659,923.46. This trade represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 174,214 shares of company stock valued at $18,397,457. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.